60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/0c/e4/6b/0ce46b91-3d22-279b-52fe-d3b1a2a47107/mza_11625791986367831883.jpg/600x600bb.jpg

TMO EPM / Hemato H9J

64 episodes

4 days ago

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

RSS

All content for TMO EPM / Hemato H9J is the property of TMO EPM / Hemato H9J and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38086306/38086306-1753387132259-2b476049091c.jpg

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

TMO EPM / Hemato H9J

33 minutes 53 seconds

3 months ago

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Discussão do artigo: "Nivolumab-AVD Versus Brentuximab

Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826" de Rutherford S JCO 2025

Apresentado por: Dra. Ilana Barcessat

Discussão por: Dr. Eduardo Burlamaqui, Dr. Rafael Faust, Dr. Guilherme Rodrigues, Dr. Pedro Moraes e Dr. Vinícius Molla